Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism
Status:
Completed
Trial end date:
2018-09-11
Target enrollment:
Participant gender:
Summary
This study is conducted to assess the efficacy and safety of SK-1403 in Hemodialysis Patients
with Secondary Hyperparathyroidism. In the first treatment period, the efficacy of SK-1403 is
assessed after 18 weeks of treatment with SK-1403 individually dose-adjusted . Safety is also
assessed during this period. Patients who completed the first treatment period proceed to the
second treatment period and receive the treatment with SK-1403 for 34 weeks. Efficacy and
safety of SK-1403 are also assessed during this period.